CITIUS ONCOLOGY, INC.
CTOR evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $97.0M
- Lead Asset:
- LYMPHIR (Approved)
What it means
What to watch
Prepared research question
What matters most for CTOR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CTOR
Citius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies, with its lead product LYMPHIR (denileukin diftitox-cdxl) approved by the FDA in August 2024 for the treatment of cutaneous T-cell lymphoma (CTCL).
Key risk: Operating losses
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for CITIUS ONCOLOGY, INC..
Similar companies
Citius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies, with its lead product LYMPHIR (denileukin diftitox-cdxl) approved by the FDA in August 2024 for the treatment of cutaneous T-cell lymphoma (CTCL).
- Lead product LYMPHIR (denileukin diftitox-cdxl) is FDA-approved for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) as of August 8, 2024 [pipeline].
- Cash and equivalents of $16.6M as of 2026-06-30 [sec].
- Total revenue of $1.5M and net income of -$8.9M as of 2026-06-30 [sec].
- Shareholders' equity of $40.4M and total debt of $10.0M as of 2026-06-30 [sec].
- Company reincorporated in Delaware and completed a merger in August 2024, changing its name to Citius Oncology, Inc. [sec_mda · as of 2026-08-14].
What works
- LYMPHIR has FDA approval and Orphan Drug Designation for CTCL, providing regulatory exclusivity and market protection [pipeline].
- The company's strategy focuses on new formulations of previously approved drugs, reducing development and clinical risks [sec · filed 2026-05-29].
- LYMPHIR's mechanism of action targets IL-2 receptor-expressing cells and depletes immunosuppressive Tregs, offering a differentiated therapeutic approach [pipeline].
What to weigh
- The company has a net loss of $8.9M as of 2026-06-30, indicating ongoing operating losses [sec].
- Cash and equivalents of $16.6M as of 2026-06-30 may be limited relative to commercialization and R&D needs [sec].
- The competitive landscape includes at least one competitor (Ligand Pharmaceuticals) for denileukin diftitox, posing market share risk [pipeline].
- The company is subject to risks common in the pharmaceutical industry, including dependence on key personnel and suppliers, and need for additional financing [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
LYMPHIR is FDA-approved for CTCL
“Regulatory Status: FDA approved August 8, 2024”
Company reincorporated and merged in August 2024
“In August 2024, we reincorporated in Delaware and completed the Merger whereby we acquired SpinCo as a wholly owned subsidiary and changed our name to Citius Oncology, Inc.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Operating losses — Net income of -$8.9M as of 2026-06-30 indicates ongoing losses [sec].
- Limited cash runway — Cash & equivalents of $16.6M as of 2026-06-30 may constrain commercialization and R&D [sec].
- Competitive pressure — At least one competitor (Ligand Pharmaceuticals) for denileukin diftitox [pipeline].
- Dependence on key personnel — Risks include dependence on key personnel and suppliers, and need for additional financing [sec_mda · as of 2026-08-14].
What to watch
- Commercial adoption and revenue growth of LYMPHIR following FDA approval in August 2024 [pipeline].
- Cash burn rate and any additional financing activities given $16.6M cash as of 2026-06-30 [sec].
- Competitive dynamics with Ligand Pharmaceuticals in the denileukin diftitox market [pipeline].
- Future earnings reports and SEC filings for updates on financial performance and operational milestones [catalyst].
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run CITIUS ONCOLOGY, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CITIUS ONCOLOGY, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.78 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$8.8M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 9,188,855 | $5.7M |
| bank of america corp /de/ | 3,835,160 | $2.4M |
| vanguard capital management llc | 534,824 | $332K |
| geode capital management, llc | 264,733 | $164K |
| vanguard fiduciary trust co | 121,910 | $76K |
| ifp advisors, inc | 107,424 | $67K |
| blackrock, inc. | 47,454 | $29K |
| northern trust corp | 45,746 | $28K |
| state street corp | 42,900 | $27K |
| ubs group ag | 36,840 | $23K |
Showing top 10 of 14 institutional holders of CITIUS ONCOLOGY, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 2.9%
- Days to cover
- 4.4
- Shares short
- 655,066
- Daily short volume (Jun 16, 2026)
- 7.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CTOR short interestGovernance
Frequently asked questions
What is the AI investment thesis for CITIUS ONCOLOGY, INC.?
Citius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies, with its lead product LYMPHIR (denileukin diftitox-cdxl) approved by the FDA in August 2024 for the treatment of cutaneous T-cell lymphoma (CTCL).
What is CITIUS ONCOLOGY, INC.'s lead drug candidate?
CITIUS ONCOLOGY, INC.'s most advanced tracked candidate is LYMPHIR (Approved) for Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).
Who is the CEO of CITIUS ONCOLOGY, INC.?
Mr. Leonard L. Mazur is the chief executive officer of CITIUS ONCOLOGY, INC. (CTOR).
Where is CITIUS ONCOLOGY, INC. headquartered?
CITIUS ONCOLOGY, INC. (CTOR) is headquartered in Cranford, NJ, United States.
What therapeutic areas does CITIUS ONCOLOGY, INC. focus on?
CITIUS ONCOLOGY, INC. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.